StockData
PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc. (PTCT) stock

PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3029% above fair value
$60.97−2.52 (-3.97%)

Close on Nov 16, 2026Market cap $5.09BP/E –Yield –

PTC Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

PTC Therapeutics's price to sales ratio was 5.4× on Nov 11, 2026, against 3.9× a year earlier. Over the last 5 years it ranged from 1.7× to 8.2×, with a median of 3.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20265.4×+1.9
2025Dec 31, 20253.4×−0.4
2024Dec 31, 20243.9×+1.3
2023Dec 29, 20232.6×−1.3
2022Dec 30, 20223.9×−1.8
2021Dec 31, 20215.7×−5.8
2020Dec 31, 202011.5×+1.6
2019Dec 31, 201910.0×+2.7
2018Dec 31, 20187.3×+2.4
2017Dec 29, 20174.9×−0.5
2016Dec 30, 20165.4×−24.6
2015Dec 31, 201529.9×−59.5
2014Dec 31, 201489.5×+78.5
2013Dec 31, 201310.9×–

More PTC Therapeutics figures

See a number that looks wrong?